miércoles, 4 de septiembre de 2019

Evaluation of a Clinical Decision Support System for the Prescription of Genetic Tests in the Gynecological Cancer Risk. - PubMed - NCBI

Evaluation of a Clinical Decision Support System for the Prescription of Genetic Tests in the Gynecological Cancer Risk. - PubMed - NCBI



 2019 Aug 21;264:704-708. doi: 10.3233/SHTI190314.

Evaluation of a Clinical Decision Support System for the Prescription of Genetic Tests in the Gynecological Cancer Risk.

Author information


1
Biomedical Informatics, Biomedical Engineering and Health Economics, Institute of Biomedicine of Seville, IBIS / Virgen del Rocío University Hospital / CSIC / University of Seville. Seville, Spain.
2
Technological Innovation Group, Virgen del Rocio University Hospital, Seville, Spain.

Abstract

Clinical Decision Support System (CDSS) has been implemented to support physicians about the medical prescription of genetic testing. CDSS is based on open source software. A CDSS for prescribing these genetic tests in BRCA1 and BRCA2 and preventing gynecological cancer risks has been designed and performed in the 'Virgen del Rocío' University Hospital. Clinical evidence demonstrates that BRCA1 and BRCA2 mutations can develop gynecological cancer, but genetic testing has a high cost to the healthcare system. The developed technological architecture integrates open source tools like Mirth Connect and OpenClinica. The system allows general practitioners and gynecologists to classify patients as low risk (they do not require a specific treatment) or high risk (they should be attended by the Genetic Council), According to their genetic risk, recommending the prescription of genetic tests. The aim main of this paper is the evaluation of the developed CDSS, getting positive outcomes.

KEYWORDS:

Breast Neoplasms; Clinical Decision Support Systems; Ovarian Neoplasms

PMID:
 
31438015
 
DOI:
 
10.3233/SHTI190314

No hay comentarios:

Publicar un comentario